CD19-CD123 compound CAR

CD19-CD123 compound CAR (also known as ICG140) is a preclinical-stage compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics (iCell ImmunityX). It is designed to target both CD19 and CD123 antigens on B-cell acute lymphoblastic leukemia (B-ALL) cells. By simultaneously targeting CD19, a well-established B-cell lineage marker, and CD123 (interleukin-3 receptor alpha), which is highly expressed on leukemic stem cells and B-ALL blasts, the therapy aims to prevent antigen-escape-mediated relapses and achieve more durable therapeutic responses.

Other names

CD19-CD123 cCARCD-19-CD123 cCARCD 19-CD123 cCARCD19-CD123 cCAR T-cellsCD-19-CD123 cCAR T-cellsCD 19-CD123 cCAR T-cellsCD19-CD123 compound CAR T-cell therapyCD-19-CD123 compound CAR T-cell therapyCD 19-CD123 compound CAR T-cell therapyCD19-CD123 compound CAR T-cellsCD-19-CD123 compound CAR T-cellsCD 19-CD123 compound CAR T-cells